OncBioMune
OncBioMune Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel cancer immunotherapy products. Their proprietary vaccine technology aims to stimulate the immune system to attack cancer cells without harming the patient. The company has a portfolio of targeted therapies, including biosimilars to blockbuster drugs, and is engaged in clinical trials for their lead product, ProscaVax™, for prostate cancer. They focus on answers for cancer through innovative research and clinical development, with a mission to become a standard of care in cancer treatment.
Industries
Nr. of Employees
small (1-50)
OncBioMune
11441 Industriplex Blvd., Suite 190, Baton Rouge, LA 70809
Products
Therapeutic prostate cancer vaccine (autologous tumor antigen with cytokine adjuvants)
A therapeutic vaccine approach using autologous tumor antigens combined with cytokine biological adjuvants to stimulate anti-tumor immunity; advanced through early clinical testing with evidence of PSA changes and safety monitoring.
Transferrin-targeted drug delivery platform (protein-drug conjugates / protein-entrapped drugs)
A platform for delivering cytotoxic agents selectively to cancer cells via transferrin/transferrin-receptor mediated uptake, including heavy-metal binding, covalent coupling and protein-entrapped drug formulations; includes a CD71-targeted protein drug complex in preclinical development.
Antisense therapeutics platform
Platform for design and development of antisense oligonucleotides and antisense RNA approaches to inhibit target mRNA, with emphasis on chemical modifications and delivery strategies to improve stability and cellular uptake.
Therapeutic prostate cancer vaccine (autologous tumor antigen with cytokine adjuvants)
A therapeutic vaccine approach using autologous tumor antigens combined with cytokine biological adjuvants to stimulate anti-tumor immunity; advanced through early clinical testing with evidence of PSA changes and safety monitoring.
Transferrin-targeted drug delivery platform (protein-drug conjugates / protein-entrapped drugs)
A platform for delivering cytotoxic agents selectively to cancer cells via transferrin/transferrin-receptor mediated uptake, including heavy-metal binding, covalent coupling and protein-entrapped drug formulations; includes a CD71-targeted protein drug complex in preclinical development.
Antisense therapeutics platform
Platform for design and development of antisense oligonucleotides and antisense RNA approaches to inhibit target mRNA, with emphasis on chemical modifications and delivery strategies to improve stability and cellular uptake.
Services
Management of early-phase oncology clinical trials including protocol development, CRO engagement, site initiation and trial registration.
Management of early-phase oncology clinical trials including protocol development, CRO engagement, site initiation and trial registration.
Expertise Areas
- Cancer immunotherapy and therapeutic vaccine development
- Clinical trial management for oncology (Phase 1–2)
- Antisense therapeutics
- Targeted drug delivery (transferrin/CD71 targeting)
Key Technologies
- Autologous tumor antigen-based therapeutic vaccines
- Cytokine adjuvants (GM-CSF, IL-2)
- Antisense oligonucleotide design
- Viral and liposomal nucleic acid delivery systems
News & Updates
OncBioMune CEO Dr. Jonathan Head presented at the 2018 Global Summit on Genitourinary Malignancies in Banff, Alberta, Canada.
The company announced the opening of a Phase 2 trial for ProscaVax in early 2019.
OncBioMune announced results of in vitro data for PGT in models of multi-drug resistant lung, pancreatic, and ovarian cancer.
OncBioMune CEO Dr. Jonathan Head presented at the 2018 Global Summit on Genitourinary Malignancies in Banff, Alberta, Canada.
The company announced the opening of a Phase 2 trial for ProscaVax in early 2019.
OncBioMune announced results of in vitro data for PGT in models of multi-drug resistant lung, pancreatic, and ovarian cancer.